Kymera prices upsized $602M public offering; net ~$656M for pipeline

Kymera Therapeutics, Inc.

Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.
Underwriters exercised option to purchase additional 1,050,000 shares in full.
Net proceeds estimated at ~$656.1M after discounts and expenses.
Cash runway extended into 2029; funds to advance degrader pipeline and working capital.
Offering expected to close December 11, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.